Looking back at the November 2020 installment of Urology Times’ Around the Practice, a virtual, monthly live case event focused on genitourinary cancers, Raoul S. Concepcion, MD, FACS, offers an update on clinical implications from two prostate cancer cases.
In November 2020, Urology Times hosted its monthly virtual case event, designed to provide insight from urology, medical oncology, and radiation oncology providers on 3 cases: metastatic castrate-sensitive prostate cancer, non-metastatic castrate-resistant prostate cancer, and de novo metastatic renal cell carcinoma.
Moderator, Raoul S. Concepcion, MD, FACS, joined Urology Times to offer an update on these cases, with potential clinical implications for the future.
To watch the full discussion on demand, visit urologytimes.com.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.